Follow us on:

Linkedin Facebook

hVIVO to hold AGM on 13 May 2024

hVIVO plc
[shareaholic app="share_buttons" id_name="post_below_content"]

hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting will be posted to shareholders today.

The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com.

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 13 May 2024 at 11am (BST).

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

hVIVO plc

hVIVO CEO Yamin ‘Mo’ Khan presenting in-person at the Jefferies Healthcare Conference

hVIVO

hVIVO reports positive results from RSV antiviral human challenge trial

hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study.
hVIVO

hVIVO officially launches full suite of its hLAB service offering

Open Orphan

hVIVO reports strong first half, delivering record revenues and margins

hVIVO plc

hVIVO release interim results on 10 September 2024, followed by analyst briefing

hVIVO plc (LON:HVO), a leading CRO in infectious and respiratory disease research, will release its interim results for H1 2024 on 10 September 2024.
hVIVO

hVIVO materially increases revenue, further improving margins

hVIVO plc (LON:HVO), a leading CRO specializing in infectious and respiratory disease products, reports a robust 30.6% revenue growth for H1 2024, driven by strong operational performance.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.